Article

Novel LED Sleep Mask "Ready for Large Clinical Trials” in Diabetic Macular Edema Patients

Author(s):

In most eyes, the mask reduced or resolved cysts in the OCT subfield.

Preliminary findings indicate that wearing a novel sleep mask containing light-emitting diodes (LEDs) may help to reduce retinal thickness in patients with diabetic macular edema (DME). A team led by J.N. Sahni, MD, of St. Paul’s Eye Unit, Royal Liverpool University Hospitals NHS Trust made the conclusion after evaluating the mask in 60 study participants.

The study compared the effect of the mask in a DME group with that in two groups of healthy volunteers, one group age 18—30 years, and another age 50–70 years. Participants wore the mask, which has a luminance of 80 cd/m2 and a wavelength of 504 nm, every night for eight hours or fewer for three months. The study also included a one-month recovery period after three months of active use.

In addition to measuring change from baseline retinal thickness with optical coherence tomography (OCT), the Liverpool team also measured change from baseline values in depression, psychological well-being, sleep, and visual acuity as well as in the number of lapses and response time required for psychomotor vigilance tasks.

The researchers found that, after three months of mask use, 67% of DME-affected eyes had a reduction or resolution of cysts in the OCT subfield with maximal pathology. They also noted that, by study end, thinning was greater in those with greater baseline retinal thickness than in those with less baseline retinal thickness (P < 0.001 for central subfield; P < 0.05 for maximal).

However, sleep disturbances and an inability to tolerate the mask led to study withdrawal in eight participants, or 13%, during the first month of the study, and in 16 participants, or 27%, during the first three months of the study. Nevertheless, the team concluded that use of the mask was acceptable for most study participants except for some healthy volunteers.

Moreover, after three months of using the mask, psychomotor vigilance task performance worsened in the group of healthy younger volunteers, and mean psychological well-being worsened in all study groups. However, the researchers reported that their study revealed no major safety issues associated with use of the mask apart from a minor reduction in daytime alertness and a moderate effect on psychological well-being.

“Preliminary data suggest a beneficial effect on retinal thickness in DMO,” the team concluded, so “This novel therapeutic approach is ready for large clinical trials.”

The published report of the study, “Safety and acceptability of an organic light-emitting diode sleep mask as a potential therapy for retinal disease,” appears in the January 2017, issue of Eye.

Related Coverage:

Diabetic Macular Edema Study: Ozurdex Outperformed Avastin, but Not Without Drawbacks

Explaining Treatment a Key Part of Helping Manage Diabetic Macular Edema

Aflibercept a ‘Powerful Tool’ in Treatment of Diabetic Macular Edema: Charles Wykoff, Retinal Consultants Houston

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.